Immunotherapy for colorectal cancer.
BACKGROUND
Advances in molecular biology have enabled specific antigens present on colorectal cells to be characterized, against which immune responses may be generated. This, in combination with our inability to significantly alter survival from this condition, has resurrected an interest in immunotherapy as a potential treatment option.


METHODS
The information contained in this review was obtained following a search of MEDLINE and BIDS (Bath Information Data System), using the key words immunotherapy, colorectal cancer, antibody, anti-idiotype, peptide vaccine, viral vector, and vaccine. In addition, journals related to this field were systematically searched.


CONCLUSIONS
A number of approaches currently constitute immunotherapeutic options for colorectal cancer. A number of treatment modalities are already in phase III studies, although clearly not all will fulfill their initial promise. Surgeons need to be aware of the advances in this rapidly expanding field, and keep an open mind as to their efficacy.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000627:therapeutic use*; D019496:Cancer Vaccines; D015179:Colorectal Neoplasms / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D016219:Immunotherapy, Adoptive